NVAX
Companies
NASDAQ
Novavax Inc.
Health Care
$6.32
-$1.55 (-19.28%)
Price Chart
Overview
About NVAX
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
Market Cap
$2.7B
Volume
36.5M
Avg. Volume
30.2M
P/E Ratio
-39.4375
Dividend Yield
0.00%
Employees
1.7K
Company Information
Latest News for NVAX
Risk & Correlation Analysis
Market Correlation
1.67
High Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, NVAX shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$2.7B
Volume36.5M
P/E Ratio-39.44
Dividend Yield0.00%
Important Dates
Next Dividend
May 10, 2019Next Earnings
February 27, 2025Related Securities
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025